Zobrazeno 1 - 10
of 50
pro vyhledávání: '"J G, Cleland"'
Autor:
A L, Clark, J G, Cleland
Publikováno v:
Heart failure reviews. 5(1)
Chronic heart failure is characterised by excess adrenergic activity that augurs a poor prognosis. The reasons for increased adrenergic activity are complex and incompletely understood. The circumstantial evidence relating increased activity to adver
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::5c6fa78e42b794a855a9421df57637e5
https://pubmed.ncbi.nlm.nih.gov/16228919
https://pubmed.ncbi.nlm.nih.gov/16228919
Publikováno v:
Heart failure monitor. 1(1)
There is now conclusive evidence that most patients with heart failure due to left ventricular systolic dysfunction should be treated with angiotensin converting enzyme (ACE) inhibitors and beta-blockers. They will also need diuretics for the control
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::4a1bafa1f1a5725107ba8b956b471112
https://pubmed.ncbi.nlm.nih.gov/12634876
https://pubmed.ncbi.nlm.nih.gov/12634876
Autor:
J G, Cleland, K, Thygesen, B F, Uretsky, P, Armstrong, J D, Horowitz, B, Massie, M, Packer, P A, Poole-Wilson, L, Rydén
Publikováno v:
European heart journal. 22(17)
Aims To determine the sequence of critical cardiovascular events in the progression of heart failure, and whether aetiology or high-dose vs low-dose lisinopril affected these pathways. Methods and Results This was a post-hoc investigation of the ATLA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bcb52f5cfa77d463f4b232fee4f4260f
https://pubmed.ncbi.nlm.nih.gov/11492982
https://pubmed.ncbi.nlm.nih.gov/11492982
Autor:
B M, Massie, P W, Armstrong, J G, Cleland, J D, Horowitz, M, Packer, P A, Poole-Wilson, L, Rydén
Publikováno v:
Archives of internal medicine. 161(2)
Treatment with angiotensin-converting enzyme (ACE) inhibitors reduces mortality and morbidity in patients with chronic heart failure (CHF), but most affected patients are not receiving these agents or are being treated with doses lower than those fou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::0a9848a99708019a6b1b528f11779ad2
https://pubmed.ncbi.nlm.nih.gov/11176729
https://pubmed.ncbi.nlm.nih.gov/11176729
Publikováno v:
European journal of heart failure. 1(2)
Carvedilol improves left ventricular (LV) function when heart failure is due to LV systolic dysfunction, but the magnitude of the response is heterogeneous among patients with coronary disease, possibly reflecting the presence or volume of hibernatin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b57227f97316379fbf009c0e0e4480e3
https://pubmed.ncbi.nlm.nih.gov/10937930
https://pubmed.ncbi.nlm.nih.gov/10937930
Autor:
P, Mylona, J G, Cleland
Publikováno v:
European journal of heart failure. 1(2)
This article reviews the design and results of REACH-1 (Research on Endothelin Antagonism in Chronic Heart Failure) and MERIT (Metoprolol controlled and Extended release, Randomised Intervention Trial in congestive Heart Failure), two recently report
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d377f20dc6871cb54aeea46257437fa5
https://pubmed.ncbi.nlm.nih.gov/10937931
https://pubmed.ncbi.nlm.nih.gov/10937931
Autor:
J G, Cleland, M, Tendera, J, Adamus, N, Freemantle, C S, Gray, M, Lye, D, O'Mahony, L, Polonski, J, Taylor
Publikováno v:
European journal of heart failure. 1(3)
The prevalence of chronic heart failure (CHF) rises with increasing age, from1% in those below 65 years of age to5% in those over 65 years of age and is a major cause of morbidity and mortality in older people. Recent European guidelines point to a m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::7250db8516fe02068142d177ac238b7f
https://pubmed.ncbi.nlm.nih.gov/10960267
https://pubmed.ncbi.nlm.nih.gov/10960267
Autor:
J G, Cleland, K, Swedberg, A, Cohen-Solal, J, Cosin-Aguilar, R, Dietz, F, Follath, A, Gavazzi, R, Hobbs, J, Korewicki, H C, Madeira, I, Preda, W H, van Gilst, J, Widimsky, V, Mareev, J, Mason, N, Freemantle, J, Eastaugh
Publikováno v:
European journal of heart failure. 2(2)
The EUROHEART programme is a rolling programme of cardiovascular surveys among the member nations of the European Society of Cardiology (ESC). These surveys will provide information on the nature of cardiovascular disease and its management. This man
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::694dc5aaa1586f51bcfd168ef7e21830
https://pubmed.ncbi.nlm.nih.gov/10856724
https://pubmed.ncbi.nlm.nih.gov/10856724
Publikováno v:
European journal of heart failure. 2(1)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::25765abaa7a0bb3c900bdf0bc8704fc5
https://pubmed.ncbi.nlm.nih.gov/10742699
https://pubmed.ncbi.nlm.nih.gov/10742699
Autor:
D J, Pennell, S G, Ray, G, Davies, M, Burgess, J, Webster, P, Slomka, P, Atkinson, J G, Cleland
Publikováno v:
International journal of cardiology. 72(3)
Carvedilol reduces mortality and improves symptoms and ejection fraction in ischemic heart failure, but its mode of action is not well defined and not all patients respond to treatment. The aim of the CHRISTMAS (Carvedilol Hibernation Reversible Isch
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::95954f7686004f05a2a59a940f145e41
https://pubmed.ncbi.nlm.nih.gov/10716137
https://pubmed.ncbi.nlm.nih.gov/10716137